T
Takao Tamura
Researcher at Kindai University
Publications - 135
Citations - 6508
Takao Tamura is an academic researcher from Kindai University. The author has contributed to research in topics: Cancer & Nivolumab. The author has an hindex of 32, co-authored 133 publications receiving 5068 citations. Previous affiliations of Takao Tamura include Kobe University.
Papers
More filters
Journal ArticleDOI
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang,Narikazu Boku,Taroh Satoh,Min Hee Ryu,Yee Chao,Ken Kato,Hyun Cheol Chung,Jen-Shi Chen,Kei Muro,Won Ki Kang,Kun-Huei Yeh,Takaki Yoshikawa,Sang Cheul Oh,Li Yuan Bai,Takao Tamura,Keun Wook Lee,Yasuo Hamamoto,Jong Gwang Kim,Keisho Chin,Do Youn Oh,Keiko Minashi,Jae Yong Cho,Masahiro Tsuda,Li-Tzong Chen,Li-Tzong Chen +24 more
TL;DR: In this phase 3 study, the survival benefits indicate that nivolumab might be a new treatment option for heavily pretreated patients with advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara,Mustafa Ozguroglu,Yung-Jue Bang,Maria Di Bartolomeo,Mario Mandalà,Min-Hee Ryu,Lorenzo Fornaro,Tomasz Olesinski,Christian Caglevic,Hyun Cheol Chung,Kei Muro,Eray Goekkurt,Wasat Mansoor,Raymond S. McDermott,Einat Shacham-Shmueli,X. Chen,Carlos Alberto Mayo,S. Peter Kang,Atsushi Ohtsu,Charles S. Fuchs,Guillermo Lerzo,Juan Manuel O'Connor,Guillermo Mendez,James Lynam,Niall C. Tebbutt,Mark Wong,Andrew Strickland,Chris Karapetis,David Goldstein,Paul Vasey,Jean-Luc Van Laethem,Eric Van Cutsem,Scott R. Berry,Mark Vincent,Bettina Muller,Felipe Rey,Angela Zambrano,Joaquin Guerra,Merete Krogh,Lene Baeksgaard,Mette Karen Yilmaz,Anneli Elme,Andrus Magi,Paivi Auvinen,Tuomo Alanko,Markus Moehler,Volker Kunzmann,Thomas Seufferlein,Peter C. Thuss-Patience,Thomas Hoehler,Georg Martin Haag,Salah-Eddin Al-Batran,Hugo Castro,Karla Lopez,Mynor Aguilar Vasquez,Mario Sandoval,Ka On Lam,Sinead Cuffe,Cathy Kelly,Ravit Geva,Ayala Hubert,Alex Beny,Baruch Brenner,Aprile Giuseppe,Alfredo Falcone,Evaristo Maiello,Rodolfo Passalacqua,Vincenzo Montesarchio,Hiroki Hara,Keisho Chin,Tomohiro Nishina,Yoshito Komatsu,Nozumo Machida,Shuichi Hironaka,Taroh Satoh,Takao Tamura,Naotaoshi Sugimoto,Haruhiko Cho,Yashushi Omuro,Ken Kato,Masahiro Goto,Ichinosuke Hyodo,Kazuhiro Yoshida,Hideo Baba,Taito Esaki,Junji Furuse,Wan Zamaniah Wan Mohammed,Carlos Hernandez Hernandez,Juan Casas Garcia,Adriana Dominguez Andrade,Katriona Clarke,Geir Hjortland,Nils Glenjen,Tomasz Kubiatowski,Jassem Jacek,Marek Z. Wojtukiewicz,Sergey Alexandrovich Lazarev,Yuri Lancukhay,Sergey Afanasayev,Vladimir Moiseyenko,Vladimir Kostorov,Svetlana Protsenko,Vadim Shirinkin,Dina Sakaeva,Natalia Fadeeva,Wei Peng Yong,Chau Hsien Matthew Ng,Barbara Robertson,Bernardo Rapaport,Graham Cohen,Lydia Dreosti,Paul Ruff,Conrad Jacobs,Gregory Landers,Waldemar Szpak,Sang-Young Roh,Jeeyun Lee,Yeul Hong Kim,Hyun Cheol Chung,Maria Alsina Maqueda,Federico Longo Munoz,Andres Cervantes Aguilar,Enrique Aranda Aguilar,Pilar Garcia Alfonso,Fernando Rivera,Jaime Feliu Batle,Roberto Pazo Cid,Kun-Huei Yeh,Jen-Shi Chen,Yee Chao,Chia Jui Yen,Oguz Kara,Suayib Yalcin,Daniel Hochhauser,Ian Chau,Al B. Benson,Veena Shankaran,Walid Shaib,Philip A. Philip,Vivek Sharma,Robert J. Siegel,Weijing Sun,Zev A. Wainberg,Ben George,Andrea J. Bullock,Samuel Myrick,Josephine Faruol,Richard M. Siegel,Timothy V. Larson,Carlos Becerra,Suresh Ratnam,Donald A. Richards,Stephen L. Riche +152 more
TL;DR: Pembrolizumab did not significantly improve overall survival compared with paclitaxel as second-line therapy for advanced gastric or gastro-oesophageal junction cancer with PD-L1 CPS of 1 or higher and had a better safety profile than pac litaxel.
Journal ArticleDOI
MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.
Toshiyuki Sakaeda,Tsutomu Nakamura,Masanori Horinouchi,Mikio Kakumoto,Nobuko Ohmoto,Toshiyuki Sakai,Yoshinori Morita,Takao Tamura,Nobuo Aoyama,Midori Hirai,Masato Kasuga,Katsuhiko Okumura +11 more
TL;DR: The serum concentration of digoxin after single oral administration was lower in the subjects harboring a mutant allele (C3435T) at exon 26 of the MDR1 gene.
Journal ArticleDOI
Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects
Tsutomu Nakamura,Toshiyuki Sakaeda,Masanori Horinouchi,Takao Tamura,Nobuo Aoyama,Toshiro Shirakawa,Masafumi Matsuo,Masato Kasuga,Katsuhiko Okumura +8 more
TL;DR: A lower plasma concentration of the substrates for CYP3A4 in subjects harboring the C3435T mutation of the MDR1 gene was suggested, reasonably explaining the lower digoxin serum concentration after administration of a single oral dose to subjects Harboring a mutant T allele.
Journal ArticleDOI
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
Kentaro Yamazaki,Michitaka Nagase,Hiroshi Tamagawa,Shinya Ueda,Takao Tamura,Kohei Murata,T. Eguchi Nakajima,Eishi Baba,Miho Tsuda,Toshikazu Moriwaki,Taito Esaki,Yasushi Tsuji,K. Muro,Koichi Taira,Tadamichi Denda,Sadao Funai,K. Shinozaki,Hideaki Yamashita,Naotoshi Sugimoto,Tatsuya Okuno,Tomohiro Nishina,M. Umeki,T. Kurimoto,Tetsuji Takayama,Akihito Tsuji,Motoki Yoshida,Ayumu Hosokawa,Yoshihiro Shibata,Koichi Suyama,Masataka Okabe,Kenji Suzuki,Nobuhiko Seki,Kentaro Kawakami,Michihiko Sato,Koshi Fujikawa,Tomonori Hirashima,Takaya Shimura,Keisei Taku,Toshio Otsuji,F. Tamura,Eiji Shinozaki,K. Nakashima,Hiroki Hara,Takahiro Tsushima,M. Ando,Satoshi Morita,Narikazu Boku,Ichinosuke Hyodo +47 more
TL;DR: FOLFIRI plus bevacizumab was non-inferior for PFS, compared with mFOLFOX6 plus beVacIZumab, as the first-line systemic treatment for mCRC.